REGENXBIO Inc. Class Action Lawsuit
Company: REGENXBIO Inc.
Ticker: (NASDAQ) RGNX
Class Action Period: February 9, 2022 - January 27, 2026
See If You Qualify For Monetary Reward
Join the REGENXBIO Inc. Class Action Lawsuit
CLASS ACTION PERIOD
February 9, 2022 - January 27, 2026
Allegations
According to the complaint, defendants provided investors with material information concerning REGENXBIO’s plan to develop and commercialize its product candidate RGX-111, a one-time gene therapy for the treatment of severe Mucopolysaccharidosis Type I, also known as Hurler syndrome. Defendants’ statements included, among other things, REGENXBIO’s positive assertions of RGX-111’s future trial success based on continuing positive biomarker and safety data from the ongoing PhaseI/II study. 3. Defendants provided these overwhelmingly positive statements to investors while, at the same time, disseminating false and misleading statements and/or concealing material adverse facts concerning the efficacy and safety of its RGX-111 trial study. On January 28, 2026, REGENXBIO issued a press release announcing that the FDA placed a clinical hold on its investigational gene therapy RGX-111. Defendants announced that an intraventricular CNS tumor was found in a participant treated in its RGX-111 Phase I/II study. Following this news, the price of REGENXBIO’s common stock declined from a closing market price of $13.41 per share on January 27, 2026, REGENXBIO’s stock price fell to $11.01 per share on January 28, 2026, a decline of 17.8% in the span of just a single day.
Eligibility
To join the lawsuit, you must have experienced a loss on REGENXBIO shares purchased within the class period specified above.
Lead Plaintiff Deadline
If you suffered a loss in REGENXBIO Inc. during the relevant time frame, you have until April 14, 2026 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
Frequently Asked Questions
- How do I join the lawsuit against REGENXBIO Inc. (NASDAQ: RGNX)?
Investors who purchased shares of REGENXBIO Inc. (NASDAQ: RGNX) during the class period (February 9, 2022 - January 27, 2026) can join by submitting their transaction details through this case page.
- Ensure your purchase falls within the class period
- Provide basic transaction and loss details
- Submit your information before the deadline
The lead plaintiff deadline for this case is April 14, 2026, so investors should act quickly to protect their rights.
- Who is eligible for the REGENXBIO Inc. lawsuit?
Anyone who bought shares of REGENXBIO Inc. (NASDAQ: RGNX) during February 9, 2022 - January 27, 2026 and suffered financial losses may qualify.
- What is the lead plaintiff deadline to join the REGENXBIO Inc. case?
The lead plaintiff deadline for the REGENXBIO Inc. lawsuit is April 14, 2026. Investors should act quickly to avoid missing this deadline.
- What is the class period for REGENXBIO Inc.?
The class period for REGENXBIO Inc. (NASDAQ: RGNX) is February 9, 2022 - January 27, 2026, during which investors may have been affected by alleged misconduct.
- Can I still join the REGENXBIO Inc. lawsuit if I sold my shares?
Yes. Investors who purchased REGENXBIO Inc. shares during February 9, 2022 - January 27, 2026 may still qualify, even if they sold their shares later.
- How much compensation can I receive from the REGENXBIO Inc. lawsuit?
Compensation depends on the total losses and the final settlement. Eligible investors in the REGENXBIO Inc. case may receive a portion of the recovery.
- Do I need to pay to participate in the REGENXBIO Inc. case?
No, most securities fraud cases involving REGENXBIO Inc. operate on a contingency basis, meaning there are no upfront costs unless there is a recovery.
- Will I need to appear in court for the REGENXBIO Inc. lawsuit?
In most cases, investors do not need to appear in court. The legal team manages the REGENXBIO Inc. case on behalf of participants.
- What documents are required for the REGENXBIO Inc. lawsuit?
To participate in the REGENXBIO Inc. lawsuit, investors may need to provide transaction records, purchase dates, number of shares, and loss details.
- What happens after I submit my trade information for REGENXBIO Inc.?
After submission, your details for the REGENXBIO Inc. case will be reviewed, and you may be contacted regarding eligibility or next steps.
- Is this legal advice for the REGENXBIO Inc. lawsuit?
No, this page provides information about the REGENXBIO Inc. case and does not constitute legal advice or create an attorney-client relationship.
- Why should I act quickly on the REGENXBIO Inc. case?
The lead plaintiff deadline for the REGENXBIO Inc. lawsuit is April 14, 2026. If you are an investor, you may have the opportunity to seek appointment as lead plaintiff or remain an absent class member.
EXPLORE MORE CASES
PayPal Holdings, Inc.
PYPL
Lead Plaintiff Deadline: April 20, 2026
Class Period: February 25, 2025 - February 2, 2026
ODDITY Tech Ltd.
ODD
Lead Plaintiff Deadline: May 11, 2026
Class Period: February 26, 2025 - February 24, 2026